Press Release: Larkspur Biosciences : Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
Research foundational to Larkspur's newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature
Read full article »
Larkspur Biosciences is a Massachusetts-based biotechnology company that researches and develops precision immunotherapies for the treatment of cancer.
Read more